Research Topics
| F Bani-SadrSummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV responseF Bani-Sadr
Groupe Hospitalier Universitaire Est, INSERM U 707, Universite Pierre et Marie Curie, UMR S 707, UPMC Paris 6, Paris, France
J Viral Hepat 19:431-5. 2012..Treatment of HCV infection should therefore be a priority in HIV-coinfected patients. Stavudine is associated with an increased risk of severe transaminitis...- [Treatment of chronic hepatitis C in HIV-infected patients]F Bani-Sadr
Groupe Hospitalier Universitaire Est Hôpital Tenon INSERM U 707, Université Pierre et Marie Curie UPMC Paris 6, Paris France
Gastroenterol Clin Biol 33:S97-S103. 2009.... - Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factorsF Bani-Sadr
Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U707, Paris, France
J Viral Hepat 15:255-60. 2008..These findings show that severe weight loss is a frequent side effect of anti-HCV therapy in HIV / HCV-coinfected patients. The underlying mechanisms remain to be identified... - Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factorsFirouzé Bani-Sadr
Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U707, France
Clin Infect Dis 46:768-74. 2008..We determined the prevalence and determinants of worsening fibrosis in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) who were receiving anti-HCV therapy... 
Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirinF Bani-Sadr
Groupe Hospitalier Universitaire Est, Universite Paris, INSERM U707, Paris, France
J Viral Hepat 14:639-44. 2007..26-0.49, P < 0.0001) and in patients receiving protease inhibitor-based antiretroviral therapy (OR, 0.51 95% CI, 0.30-0.86, P = 0.0114). Zidovudine discontinuation could help to avoid anaemia associated with anti-HCV therapy...- Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factorsFirouzé Bani-Sadr
Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM V707, Paris, France
AIDS 20:525-31. 2006..To evaluate the prevalence and severity of steatosis and possible interactions between steatosis, host factors, viral factors, and treatment for HIV infection in HIV-hepatitis C virus (HCV) coinfected patients... - Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatmentFirouzé Bani-Sadr
INSERM U707, Faculte de Medecine Hopital Saint Antoine, Paris, France
Clin Infect Dis 41:1806-9. 2005..02), and elevated total bilirubin level (OR, 7.9; 95% CI, 1.08-93.3; P<.03). Didanosine should thus not be given to patients with cirrhosis, particularly when treatments for HCV and HIV infections have to be administered concomitantly... - Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapyFirouzé Bani-Sadr
Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U444, France
J Acquir Immune Defic Syndr 40:47-52. 2005..To evaluate the incidence, clinical features, and risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving anti-HCV therapy... - Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virusF Bani-Sadr
Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Paris, France
Clin Infect Dis 39:1062-4. 2004..The use of combination therapy with lamivudine and tenofovir for the treatment of HBV infection is very promising in the treatment of HIV/HBV coinfection... - Persistently normal alanine aminotransferase levels in HIV/HCV-coinfected patients: the role of steatosisF Bani-Sadr
Groupe Hospitalier Universitaire Est, INSERM U 707, Universite Pierre et Marie Curie, Paris, France
HIV Med 10:417-21. 2009..We analysed factors associated with persistently normal ALT levels, defined as at least three consecutive normal ALT values over a 6-month period, in a group of 381 HIV/HCV-coinfected patients... - [Metastatic cancer of the prostate in a 40-year-old HIV-infected male patient]A Furco
Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Paris
Presse Med 32:644-5. 2003..Cancer of the prostate in HIV-infected patients has rarely been reported in the literature... - [Metastatic cancer of the prostate in a young 40 year-old HIV-infected male patient]A Furco
Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Paris
Presse Med 32:930-1. 2003..Cancer of the prostate in HIV-infected patients has rarely been reported in the literature... - Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008L Michel
INSERM U669, Paris, France
J Viral Hepat 17:650-60. 2010....